Scientific article
Open access

Nécrose rétinienne aiguë due au virus de la varicelle et du zona et vaccin recombinant contre le zona

Other title[Varicella-zoster virus (VZV) acute retinal necrosis and recombinant zoster vaccine]
Published inRevue médicale suisse, vol. 18, no. 777, p. 714-717
Publication date2022-04-13

Varicella zoster virus (VZV) is responsible for chickenpox. Like all herpes viruses, after primary infection it enters into latency and can be reactivated afterwards. Many forms of symptomatic reactivation of VZV exist including acute retinal necrosis (ARN), an ophthalmic emergency which can lead to blindness. ARN is treated starting with high-dose intravenous acyclovir then with oral valaciclovir for a total duration of up to 3 months. Symptomatic reactivations of VZV are public health issues. The new Swiss 2022 vaccination plan includes the recombinant vaccine Shingrix. It effectively prevents VZV symptomatic reactivations even in elderly and immuno suppressed patients.

  • Aged
  • Chickenpox / prevention & control
  • Chickenpox Vaccine / therapeutic use
  • Herpes Zoster / drug therapy
  • Herpes Zoster / prevention & control
  • Herpes Zoster Vaccine / therapeutic use
  • Herpesvirus 3, Human / physiology
  • Humans
  • Retinal Necrosis Syndrome, Acute / drug therapy
  • Vaccines, Synthetic / therapeutic use
Citation (ISO format)
TIRAT, William Robert, SCHIBLER, Manuel. Nécrose rétinienne aiguë due au virus de la varicelle et du zona et vaccin recombinant contre le zona. In: Revue médicale suisse, 2022, vol. 18, n° 777, p. 714–717. doi: 10.53738/REVMED.2022.18.777.714
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation02/08/2023 7:52:34 AM
First validation08/02/2023 2:20:32 PM
Update time08/02/2023 2:20:32 PM
Status update08/02/2023 2:20:32 PM
Last indexation01/18/2024 12:33:14 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack